My Top 3 Biotech Stocks for May 2026

The article highlights three biotech names with distinct catalysts: Schrödinger reported $256 million in 2025 revenue, including $200 million of software revenue, and guided for 10% to 15% ACV growth in 2026 to $218 million-$228 million. Sarepta generated $1.86 billion in 2025 net product revenue, including $899 million from Elevidys, while maintaining 2026 guidance of $1.2 billion-$1.4 billion despite regulatory scrutiny. NRX Pharmaceuticals has upcoming FDA decisions and new trial catalysts, but remains highly speculative.

Analysis

The cleaner read-through is that the market is rewarding biotech names with either self-funding or near-term de-risking, not just science optionality. SDGR’s real edge is that software cash flow converts the company from a pure burn story into a platform story, which should compress funding-risk discounts and make every pipeline update more investable; that said, the valuation now depends on proving internal drug discovery can create a second engine, not just perpetuate the software annuity.

SRPT is the opposite setup: a commercial asset with binary overhang. The second-order effect is that every additional safety clarification helps not only the stock, but also the broader gene-therapy cohort by reducing the implied regulatory penalty on the category; if the narrative stabilizes, capital could rotate back into platform/genetic medicine names that have been ignored because of headline risk. But if any new liver-safety signal emerges, the multiple can re-rate down faster than revenue growth can offset it, because the market will focus on durability of the franchise rather than the current top line.

NRXP is a catalyst-driven lottery ticket where timing matters more than intrinsic value. The regulatory path creates a short-dated event window over the next 1-2 quarters, but the financing risk means positive headlines may still fail to sustain if dilution is needed before commercialization. The contrarian point is that the setup may be better as a volatility event than a directional long: approval or trial progress can gap the stock, but the base case remains a capital structure story until there is evidence of revenue-backed execution.

Broadly, the article underweights how much this environment favors companies with visible cash flow and multiple shots on goal. In a market where the cost of capital is easing but still high for microcaps, the winners are likely to be names that can self-fund through the next 12 months of catalysts, while the losers are the perpetual burn stories that need both good data and good financing conditions at the same time.

Key Decisions for Investors

• Long SDGR for 6-12 months into guidance updates: better risk/reward than pure preclinical AI names because software revenue lowers dilution risk; use weakness on broad biotech selloffs to accumulate, with upside tied to multiple expansion if pipeline catalysts land.
• Own SRPT only as a tactical trade, not a core hold: consider a reduced-size long or call spread ahead of regulatory milestones if you believe safety scrutiny is peaking; trim aggressively on any renewed adverse-event headline because downside can reprice in days.
• Use NRXP as a catalyst-volatility trade rather than a fundamental long: buy limited-risk calls or a call spread into the FDA decision window over the next 1-2 quarters, sized small because financing overhang can cap post-news follow-through.
• Pair long SDGR / short a basket of cash-burning AI-biotech names with no revenue for 3-6 months: thesis is that the market will continue to reward self-funding platforms while punishing names that need continuous equity access.